Novo Nordisk Launches Australian Phase 3 Trial for Oral Insulin in Type 1 Diabetes 2 years ago AnaIn BreakthroughsClinical TrialsResearch UpdatesTop Stories
Oxford Nanopore and BioMarin Partner to Advance Genomic Diagnostics for Rare Disease 2 years ago AnaIn Clinical TrialsFDA ApprovalsPartnershipsResearch UpdatesTop Stories
FDA Approves Optune Lua for Metastatic Non–Small Cell Lung Cancer, While Funding and Oncology Advances Dominate the Biopharma Landscape 2 years ago AnaIn BreakthroughsClinical TrialsFunding RoundsInnovationTechnologyTop StoriesVenture Capital
FDA Grants Orphan Drug Designation to Novavax’s mRNA Vaccine Candidate for Rare Infectious Disease 2 years ago AnaIn FDA ApprovalsResearch UpdatesTop Stories
Biogen and Denali Therapeutics Expand Neurodegenerative Disease Pipeline with Strategic Partnership 2 years ago AnaIn Clinical TrialsPartnershipsResearch UpdatesTop Stories
October Deal Frenzy: Biotech Giants Strike Billion-Dollar Partnerships and Pave New R&D Paths 2 years ago AnaIn BreakthroughsDealsPartnershipsPharma Industry UpdatesTop Stories
KSQ Therapeutics Receives FDA Clearance to Advance CRISPR-Edited Cell Therapy for Advanced Solid Tumors 2 years ago AnaIn Biopharma HighlightsBreakthroughsClinical TrialsFDA ApprovalsTop Stories
FDA Advisory Panel Recommends Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy 2 years ago AnaIn Biopharma HighlightsFDA ApprovalsResearch UpdatesTop Stories
US Biotech Faces VC Slowdown, but Startups Adapt with New Strategies 2 years ago AnaIn Biopharma HighlightsFunding RoundsTop StoriesVenture Capital
Vertex and CRISPR Therapeutics Secure First-Ever FDA Approval for CRISPR-Based Therapy in Sickle Cell Disease 2 years ago AnaIn Biopharma HighlightsFDA ApprovalsResearch UpdatesTop Stories
Griffith University Launches $14M Clinical Trial for Spinal Cord Injury Using Nasal Cell Transplants 2 years ago AnaIn Clinical Trials
Replicor Secures $180M Series C to Expand RNA Amplification Platform Beyond Hepatitis B 2 years ago AnaIn Pharma Industry UpdatesTop StoriesVenture Capital
FDA Grants RMAT Designation to ExoGene’s Exosome-Based Gene Therapy for ALS 2 years ago AnaIn FDA ApprovalsInvestmentsPharma Industry Updates
mRNA-4157/V940 Shows Durable Response in Melanoma: Moderna and Merck’s Cancer Vaccine Hits Key Milestone 2 years ago AnaIn Clinical TrialsPharma Industry Updates
